基本信息
浏览量:1160
职业迁徙
个人简介
Dr. Zhou's research focuses on molecular genetics of human cancer.Dr. Zhou holds professional memberships with American Association for Cancer Research and American Association for Advancement of Science.
Research
Dr. Zhou's laboratory studies the functions of novel tumor suppressor genes in the context of specific human cancers. His group recently discovered a tumor suppressor gene called Sox7 that is inactivated in both colon and prostate tumors, thus allowing the aberrant activation of WNT signaling. However, the gene's protein product, Sox7, acts as a regulator of a subset of genes that are specifically expressed in prostate tumors, including the androgen-responsive genes. Dr. Zhou's team is currently investigating the specific effect of Sox7 inactivation in prostate cancers.
In a related area of interest, Dr. Zhou is also intrigued by the molecular basis for the tumor-type specific inactivation of tumor suppressor genes. A recent area of focus is the LKB1 tumor suppressor, which is preferentially inactivated in non-small cell lung cancer (NSCLC). The group discovered a potential mechanism that could explain the lack of LKB1 mutations in other major tumor types. In addition, as each mechanism is studied, the opportunities for developing new and better targeted cancer therapies increase, ultimately providing benefits to cancer patients. For example, Dr. Zhou is currently developing a unique therapeutic approach for NSCLC tumors that lack the LKB1 function.
Research
Dr. Zhou's laboratory studies the functions of novel tumor suppressor genes in the context of specific human cancers. His group recently discovered a tumor suppressor gene called Sox7 that is inactivated in both colon and prostate tumors, thus allowing the aberrant activation of WNT signaling. However, the gene's protein product, Sox7, acts as a regulator of a subset of genes that are specifically expressed in prostate tumors, including the androgen-responsive genes. Dr. Zhou's team is currently investigating the specific effect of Sox7 inactivation in prostate cancers.
In a related area of interest, Dr. Zhou is also intrigued by the molecular basis for the tumor-type specific inactivation of tumor suppressor genes. A recent area of focus is the LKB1 tumor suppressor, which is preferentially inactivated in non-small cell lung cancer (NSCLC). The group discovered a potential mechanism that could explain the lack of LKB1 mutations in other major tumor types. In addition, as each mechanism is studied, the opportunities for developing new and better targeted cancer therapies increase, ultimately providing benefits to cancer patients. For example, Dr. Zhou is currently developing a unique therapeutic approach for NSCLC tumors that lack the LKB1 function.
研究兴趣
论文共 862 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Junghui Koo,Carol Tucker-Burden, Melissa Roy, Chunzi Huang,Wei Zhou,Melissa Gilbert-Ross,Haian Fu,Suresh S. Ramalingam,Adam I. Marcus
Cancer Researchno. 6_Supplement (2024): 4047-4047
Foodsno. 1402 (2023): 1402-1402
crossref(2023)
Qi Long,Jianpeng Xu,Adeboye O. Osunkoya, Soma Sannigrahi,Brent A. Johnson,Wei Zhou,Theresa Gillespie,Jong Y. Park,Robert K. Nam, Linda Sugar,Aleksandra Stanimirovic,Arun K. Seth,
crossref(2023)
Gui-long Wu,Fen Liu,Na Li, Qian Fu,Cheng-kun Wang,Sha Yang,Hao Xiao,Li Tang,Feirong Wang,Wei Zhou,Wenjie Wang, Qiang Kang,
Advanced science (Weinheim, Baden-Wurttemberg, Germany)no. 36 (2023): n/a-n/a
crossref(2023)
biorxiv(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn